Skip to content

Fuzzy Wale Compression Stockinet to Promote Healing Following Transtibial Amputation for Peripheral Arterial Disease

A Pilot Study of Fuzzy Wale Compression Stockinet to Evaluate Healing Following Transtibial Amputation for Peripheral Arterial Disease

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06308562
Enrollment
40
Registered
2024-03-13
Start date
2025-07-07
Completion date
2026-12-31
Last updated
2026-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Arterial Disease

Brief summary

The objective of this study is to determine if using Fuzzy Wale compression stockinet can assist in reducing the healing time and decrease costs in transtibial amputation patients as compared to standard of care treatment compression stocking.

Interventions

DEVICEFuzzy Wale Compression Stockinet

EdemaWear is a tubular, circular knit elastic stockinet fabricated with elastic, vertically oriented fuzzy wales, with the compression provided by the elastic, horizontal oriented Lycra® spandex yarns knitted in between. The stockinet is applied from the foot to the popliteal crease, over the affected area. EdemaWear can be applied in direct contact with the skin or over a wound care dressing. Sizing is based on leg circumference. EdemaWear is indicated for edema management of various etiologies (lymphedema, chronic venous insufficiency, congestive heart failure), and optimizing wound healing. The stockinette is often combined with other boxed compression sets. The manufacturer's stated dosage of EdemaWear is 8-12mmHg when used alone.

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \>18 years * Male and female * Transtibial amputation expected. * Peripheral arterial disease and Transcutaneous partial pressure of oxygen (TCP02, if performed) * Ability of subject to give appropriate consent or have an appropriate representative available to do so.

Exclusion criteria

* Known allergies to any of the components of the compression. * Terminal illness or current cancer therapy with chemotherapy * Inability to undergo ongoing care in Rochester. * Lack of cognitive ability to follow instructions or monitor residual limb. * Vulnerable study population * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Surgical site infection8 weeks post-operativelyNumber of subject presenting with surgical site infections following transtibial amputation.
Wound dehiscence8 weeks post-operativelyNumber of subject presenting with wound dehiscence following transtibial amputation.
Pain control8 weeks post-operativelyPain control during healing following transtibial amputation will be measured using the Visual Analog Scale (VAS). VAS scores range from 0-10 with 10 being the worst possible pain and 0 being no pain.
Time to prosthetic fitting8 weeks post-operativelyNumber of days from transtibial amputation to prosthetic fitting.

Secondary

MeasureTime frameDescription
Length of hospital stay8 weeks post-operativelyNumber of days from transtibial amputation to hospital discharge.

Countries

United States

Contacts

Primary ContactVascular Research Team
Melin.Matthew@mayo.edu(507) 538-7425
Backup ContactMatthew Melin, M.D.
Melin.Matthew@mayo.edu(507) 266-6717

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026